Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 15/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17670590 | 1.00 | LMNA (0.46) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL19501270 | 0.83 | ALDH1A1 (0.50) | LMNASLC15A2IMPDH2FNTAFNTB | |
| SCHEMBL17706760 | 0.78 | LMNA (0.48) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL21176647 | 0.78 | LMNA (0.48) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL8468128 | 0.78 | LMNA (0.48) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL17670755 | 0.78 | MEN1 (0.50) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL17670753 | 0.78 | MEN1 (0.50) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL11751993 | 0.78 | LMNA (0.48) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL8927123 | 0.78 | FNTA (0.55) | LMNASLC15A2IMPDH2EGLN1ALKBH5 | |
| SCHEMBL17706805 | 0.78 | LMNA (0.48) | LMNASLC15A2IMPDH2EGLN1ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| EP-3795566-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3359528-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-108349904-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2021-08-19 | — | — | US | disclosed |
| CN-113024467-A | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-113004205-A | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3795566-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Mitobridge, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190337920-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-11-07 | — | — | US | disclosed |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2017-10-26 | — | — | US | disclosed |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2017-10-26 | — | — | US | disclosed |
| WO-2017062468-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057658-A9 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016057660-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057658-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337920-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | LMNA 607/4885SLC15A2 3127/4885IMPDH2 3373/4885 |
| US-10188627-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | LMNA 830/4885SLC15A2 2084/4885IMPDH2 2444/4885 |
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | LMNA 607/4885SLC15A2 3127/4885IMPDH2 3373/4885 |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | LMNA 816/4885SLC15A2 3459/4885IMPDH2 4003/4885 |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARA, PPARD | LMNA 816/4885SLC15A2 3459/4885IMPDH2 4003/4885 |
| US-20170304255-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | LMNA 830/4885SLC15A2 2084/4885IMPDH2 2444/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | LMNA 607/4885SLC15A2 3127/4885IMPDH2 3373/4885 |
| US-20170305894-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | LMNA 918/4885SLC15A2 2633/4885IMPDH2 3567/4885 |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | LMNA 607/4885SLC15A2 3127/4885IMPDH2 3373/4885 |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | LMNA 607/4885SLC15A2 3127/4885IMPDH2 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.